GH Research PLC (GHRS) vs Stoke Therapeutics, Inc. (STOK)
A side-by-side comparison of GH Research PLC and Stoke Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GHRS
GH Research PLC
$21.52HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
STOK
Stoke Therapeutics, Inc.
$24.37HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — GHRS vs STOK
growth of $100 · dividends reinvested · last 5yGHRS +15.2% (+2.9%/yr)STOK -29.9% (-6.9%/yr)GHRS compounded faster over this window
GHRS STOK
GHRS vs STOK: by the numbers
- •STOK is the larger company ($1.57B vs $1.48B market cap).
- •Both run net losses; GHRS's is the smaller (0.00% vs -753.60% net margin).
Metrics side by side
Valuation
| Metric | GHRS | STOK |
|---|---|---|
| P/S ratio | N/A | 57.00 |
| P/B ratio | 4.10 | 4.55 |
Profitability
| Metric | GHRS | STOK |
|---|---|---|
| Gross margin | 0.00% | 100.00% |
| Operating margin | 0.00% | -11.16% |
| Net margin | 0.00% | -753.60% |
| ROE | -17.32% | -60.17% |
| ROIC | -19.87% | -63.12% |
Growth (annualized)
| Metric | GHRS | STOK |
|---|---|---|
| Total return CAGR (5Y) | 0.52% | -0.24% |
Frequently asked
- How have GHRS and STOK total returns compared?
- Over the past 5 years, GHRS delivered 0.52% and STOK delivered -0.24% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.